. 2023 Aug 25;12(5):e230035. doi: 10.1530/ETJ-23-0035
This work is licensed under a Table 1.
Clinical characteristics of participants.
| AIT | Control | P | |
|---|---|---|---|
| Age (years) | 47 (35–55) | 48 (35–56) | 0.844 |
| Sex (females, %) | 25, 83.3% | 24, 82.8% | 0.953 |
| BMI (kg/m2) | 24.97 (22.85–26.91) | 24.65 (21.74–26.50) | 0.306 |
| TSH (mIU/L) | 1.83 (1.14–3.33) | 1.35 (1.03–2.03) | 0.095 |
| FT3 (pmol/L) | 4.33 (4.07–4.62) | 4.58 (4.15–4.76) | 0.252 |
| FT4 (pmol/L) | 12.64 (11.39–13.33) | 13.44 (12.11–14.24) | 0.081 |
| TPOAb (mIU/L) | 227.98 (79.55–420.26) | 0.99 (0.61–1.58) | <0.001 |
| TgAb (mIU/L) | 215.40 (38.34–632.53) | 1.36 (0.82–2.57) | <0.001 |
| Melatonin (pg/mL) | 26.59 (19.86–35.46) | 23.35 (18.81–31.92) | 0.331 |
The figure in brackets represents the interquartile range (IQR) of the variable.
FT3,: free triiodothyronine; FT4, :free thyroxine; TgAb, thyroglobulin antibodies; TPOAb, thyroid peroxidase antibodies; TSH, thyroid-stimulating hormone.